Additional file 1 of XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

  • Lapo Alinari (Creator)
  • Andrés J M Ferreri (Creator)
  • Ken H Young (Creator)
  • Fredrick Hagemeister (Creator)
  • Feng Zhu (Creator)
  • Lan V Pham (Creator)
  • Jooryung Huh (Contributor)
  • Michael B. Møller (Creator)
  • Miguel A Piris (Creator)
  • Karen Dybkær (Creator)
  • Yong Li (Creator)
  • Youli Zu (Creator)
  • Govind Bhagat (Creator)
  • Bing Xu (Creator)
  • Eric D. Hsi (Creator)
  • J Han van Krieken (Contributor)
  • Mingzhi Zhang (Contributor)
  • Zijun Y Xu-Monette (Creator)
  • Alexandar Tzankov (Creator)
  • Carlo Visco (Creator)
  • William W L Choi (Creator)
  • Michael Andreeff (Creator)
  • Jane N Winter (Creator)
  • Wayne Tam (Creator)
  • Benjamin M Parsons (Creator)
  • Manman Deng (Contributor)
  • April Chiu (Creator)
  • Xiaosheng Fang (Contributor)
  • Maurilio Ponzoni (Creator)

Dataset

Description

Additional file 1. Table S1: Clinicopathologic and molecular characteristics of DLBCL patients with high or low XPO1 expression. Table S2: Significantly differentially expressed genes between XPO1high and XPO1low DLBCL patients with concurrent TP53 mutation and high MYC expression. Figure S1: Biomarker study for XPO1 and selinexor. (A–B) XPO1high expression showed significant adverse prognostic impact in the ABC subtype but not the GCB subtype of DLBCL. (C) XPO1high expression showed a trend of unfavorable prognostic effect on PFS in MYC-rearranged (MYC-R+) DLBCL. (D) XPO1high expression was associated with significantly poorer survival in DLBCL patients with wild type (Wt) TP53. (E) ABC-DLBCL and GCB-DLBCL cells showed similar sensitivity to the cytotoxicity of selinexor. (F) TP53 mutation (Mut-TP53) significantly reduced the anti-lymphoma efficacy of selinexor in HGBCL-DH cells. IC50 values were calculated by GraphPad Prism 8 based on the cell viability data after 72-hour treatment.
Date made available1 Jan 2020
PublisherFigshare

Cite this